Literature DB >> 3144213

Measures of the inflammatory response in cryptogenic fibrosing alveolitis.

C F Pantin1, S O Valind, M Sweatman, R Lawrence, C G Rhodes, L Brudin, A Britten, J M Hughes, M Turner-Warwick.   

Abstract

Cryptogenic fibrosing alveolitis (CFA) is characterized by interstitial fibrosis and parenchymal inflammation. Eleven patients with CFA (10 proved by lung biopsy) were followed over 2 yr using clinical symptoms, radiographic change, and pulmonary function tests to adjust their treatment. Lung lavage, positron camera (PET) measurements of regional extravascular lung density (Dev), pulmonary blood volume (Vb), and the metabolic rate for 18F-deoxyglucose (MRglc), clearance of 99mTc-diethylenetriaminepentacetate (99mTc-DTPA) aerosol, and lung uptake of 67Ga were measured initially and at the end of the first year to give a profile of the inflammatory response. Compared with normal subjects, there was an increased percentage of neutrophils and eosinophils in the lung lavage, increased Dev (p less than 0.002) with no significant difference in Vb, increased MRglc (p less than 0.02), 99mTc-DTPA clearance (p less than 0.002), and 67Ga uptake (p less than 0.02). The smallest increases in Dev were seen in the two patients with most destruction shown by lung biopsy. There were inverse correlations between Dev and both FVC and TLC, but a direct correlation between Vb and transfer factor. 99mTc-DTPA clearance changed concordantly with clinical status and radiographic and respiratory function changes during the first year. If glucose utilization (MRglc) remained in the normal range between the initial and first yearly assessment, the patient improved or remained stable during the second year as shown by clinical status and radiographic and respiratory function measurements. If it rose or remained high, the patient's condition deteriorated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144213     DOI: 10.1164/ajrccm/138.5.1234

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

Review 1.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

Review 2.  18F-fluorodeoxyglucose PET scans in lung cancer.

Authors:  J M Hughes
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

3.  Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP).

Authors:  N Mogulkoc; M H Brutsche; P W Bishop; B Murby; M S Greaves; A W Horrocks; M Wilson; C McCullough; M Prescott; J J Egan
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

4.  Quantitative pulmonary gallium scanning in interstitial lung disease.

Authors:  S C Ramsay; M G Yeates; W M Burke; D H Bryant; G W Morgan; S N Breit
Journal:  Eur J Nucl Med       Date:  1992

5.  Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis.

Authors:  Barry S Shea; Clemens K Probst; Patricia L Brazee; Nicholas J Rotile; Francesco Blasi; Paul H Weinreb; Katharine E Black; David E Sosnovik; Elizabeth M Van Cott; Shelia M Violette; Peter Caravan; Andrew M Tager
Journal:  JCI Insight       Date:  2017-05-04

6.  Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography.

Authors:  L H Brudin; S O Valind; C G Rhodes; C F Pantin; M Sweatman; T Jones; J M Hughes
Journal:  Eur J Nucl Med       Date:  1994-04

7.  Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.

Authors:  R M Silver; D A Wilson; T Akter; I Atanelishvili; J T Huggins; K Kajdasz; K B Highland; P J Nietert; G S Bogatkevich
Journal:  ACR Open Rheumatol       Date:  2019-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.